 "Sun Pharma hits 5-month low; stock slips 7%")
Shares of Sun Pharmaceutical Industries hit an over five-month low of Rs 475 per share, slipping 7%, and falling 9% from its early morning high on Tuesday on the back of heavy volumes. The stock was trading at its lowest level since June 6, 2018, declining 11% in past three days.
Sun Pharma was up 2% to Rs 521 in intra-day trade after the drug maker said that it has settled Modafinil antitrust litigation with certain US plaintiffs.
“Sun Pharmaceutical Industries and one of its wholly-owned subsidiaries have entered into settlements with certain plaintiffs in the In re Modafinil antitrust litigation matter pending in the United States district Court for the Eastern district of Pennsylvania,” the company said in a regulatory filing on Monday after market hours.
The settlements extend to all claims brought by the direct purchaser plaintiffs. The terms of the settlements are confidential, it added.
Sun Pharma had reported a loss of Rs 2.2 billion during July-September quarter (Q2FY19) due to a one-time provision of Rs 12.1 billion for the estimated settlement amount payable to all the remaining plaintiffs related to the Modafinil antitrust litigation in the US.
Post Q2FY19 results, the stock underperformed the market, by falling 19% from Rs 590 on November 12, against 1.6% rise in the S&P BSE Sensex. It corrected 30% from its 52-week high level of Rs 679 touched on September 6 this year.
At 11:24 am; Sun Pharma was trading 6% lower at Rs 481, against 0.09% decline in the benchmark index. The trading volumes on the counter more than doubled with a combined 22.49 million equity shares changed hands on the BSE and NSE so far.
Sun Pharma was up 2% to Rs 521 in intra-day trade after the drug maker said that it has settled Modafinil antitrust litigation with certain US plaintiffs.
“Sun Pharmaceutical Industries and one of its wholly-owned subsidiaries have entered into settlements with certain plaintiffs in the In re Modafinil antitrust litigation matter pending in the United States district Court for the Eastern district of Pennsylvania,” the company said in a regulatory filing on Monday after market hours.
The settlements extend to all claims brought by the direct purchaser plaintiffs. The terms of the settlements are confidential, it added.
Sun Pharma had reported a loss of Rs 2.2 billion during July-September quarter (Q2FY19) due to a one-time provision of Rs 12.1 billion for the estimated settlement amount payable to all the remaining plaintiffs related to the Modafinil antitrust litigation in the US.
Post Q2FY19 results, the stock underperformed the market, by falling 19% from Rs 590 on November 12, against 1.6% rise in the S&P BSE Sensex. It corrected 30% from its 52-week high level of Rs 679 touched on September 6 this year.
At 11:24 am; Sun Pharma was trading 6% lower at Rs 481, against 0.09% decline in the benchmark index. The trading volumes on the counter more than doubled with a combined 22.49 million equity shares changed hands on the BSE and NSE so far.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%